GE Healthcare Announces FDA Approval For Use Of DaTscan In Suspected Dementia With Lewy Bodies

GE Healthcare (GE) announced on Thursday that DaTscan was approved by FDA for use in patients with suspected Dementia with Lewy Bodies or DLB.

DaTscan is a radiopharmaceutical imaging agent that works by binding to dopamine transporters or DaT in the brain.

Earlier, DaTscan was indicated for use with single photon emission computed tomography imaging to visualize dopamine transporters in the brains with suspected Parkinsonian syndromes.

The company said clinical signs and symptoms of DLB can be atypical and overlap with other forms of dementia. Often up to 70 percent of patients with DLB are being misdiagnosed, often as having Alzheimer's Disease.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Integrated energy company Chevron reported Friday that profit for the fourth quarter increased 25 percent from last year, reflecting 17 percent revenue growth amid higher realizations and higher margins on refined product sales. Adjusted earnings per share missed analysts' estimates, while quarterly revenues topped it. Reno, Nevada-based ZLINE Kitchen and Bath has expanded its recall of gas ranges citing serious risk of injury or death from carbon monoxide poisoning, the U.S. Consumer Product Safety Commission announced. The recall now includes about 30,000 units of ZLINE gas ranges, including about 28,000 units... The Food and Drug Administration's independent advisory committee unanimously recommended replacing the current original COVID vaccines used in the U.S. for primary shots with new bivalent omicron shots authorized as boosters, reports said. The committee also considered the proposal for annual COVID vaccination, however, didn't vote on it.
Follow RTT